Jerini starts cirrhosis Phase IIa

Jerini (Berlin, Germany) began a European Phase IIa trial of its Icatibant to treat late-stage liver cirrhosis and hepato-renal syndrome. Icatibant is a bradykinin receptor antagonist that Jerini lice...